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ABSTRACT
The regenerative ability of planarians depends largely on its complex signaling pathways. The Wnt pathway 
regulates the anterior/posterior (A/P) polarity formation after regeneration, while the MAPK pathway plays a role in 
anterior regeneration. This experiment uses various drugs to disrupt the aforementioned pathways. Imatinib targets 
the receptor tyrosine kinases (RTKs), a common type of surface receptors that play a role in the Wnt pathway. 
PZQ is expected to affect the Wnt noncanonical calcium pathway. EHT 1864 inhibits Rac1, a GTPase involved 
in the noncanonical PCP pathway. Finally, U0126 disrupts the MAPK pathway and blastemic cell differentiation. 
After drug treatment, abnormal planarian regeneration is expected. The drug assays demonstrated that while both 
Imatinib and PZQ have no effect on planarian regeneration, EHT 1864 under high concentration has a potent 
effect on the viability of planarians during regeneration. Furthermore, U0126 caused cyclopia, a condition in which 
organisms only develop one eye instead of the normal number, in planarians under high concentrations. These 
observations suggest that the RTKs play a limited role in planarian regeneration, Rac1 plays a greater role than just 
A/P determination during regeneration, and that U0126 affects eye and head regeneration. Our assays with PZQ 
also show that different species of planarians might have different noncanonical calcium pathways.
L’abilité regénérative des planaires dépend largement sur la complexité des ses voies de signalisation. La voie 
des Wnt contrôle la formation de la polarité des potentiels d’action après la regénération, alors que la voie de la 
MAPK joue un rôle dans la regénération. L’imatinib cible les RTK, eux-mêmes jouant un rôle dans la voie des Wnt. 
Praziquantel est attendu d’affecter la voie de calcium non canonique des Wnt. L’EHT 1864 inhibe la Rac1, un 
GTPase impliqué dans la voie non canonique du PCP. Finalement, U0126 perturbe la voie de la MAPK, l’activité 
de laquelle induit la différentiation des cellules souches blastémiques. Après traitement avec de la drogue, de la 
regénération anormale des planaires est attendue. Les essais des drogues ont démontré que, bien que Imatinib et 
PZQ n’ont pas d’effets sur la regénération des planaires, l’EHT 1864 en haute concentration a un effet potent sur 
la viabilité des planaires durant la regénération. De plus, l’U0126 a causé la cyclopie chez les planaires en haute 
concentration. Ces observations suggère que les RTK jouent un rôle limité dans la regénération de planaires, 
la Rac1 joue un rôle plus important que simplement déterminer des potentiels d’action durant la regénération et 
l’U0126 affecte les regénérations des yeux et de la tête. Nos découvertes indiquent aussi des incohérences avec 
une étude par un autre groupe au sujet des effets du PZQ sur la formation polaire des planaires.
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INTRODUCTION 
Planarians have been long known for their regenerative 
abilities; even a fragment as tiny as 1/279th of the 
planarian body can fully regenerate into a complete 
planarian1. A large number of pluripotent, highly 
undifferentiated cells called neoblasts are distributed 
throughout the planarian body; neoblasts are able to 
differentiate into all planarian cell types and upon injury, 
differentiate and seem to migrate in response to wound 
signals1. Central to planarian regeneration are the Wnt 
pathway and the MAPK pathway that determine the 
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polarity of planarian regeneration after receiving injury. 
The Wnt pathway can be categorized further into three 
pathways: the canonical pathway, the noncanonical 
calcium pathway, and the noncanonical PCP pathway.  
The canonical pathway is marked by the presence of the 
protein β-catenin. The binding of the Wnt ligand to the 
Frizzled receptor activates the Dsh protein, and through 
a series of cascades promotes cytoplasmic β-catenin 
accumulation. β-catenin binds to the transcription factor 
TCF and acts as a cotranscription factor2. Studies on 
the planarian species S. mediterranea have found that 
the canonical pathway is active in the posterior end, 
while it is suppressed by sFRP, a protein expressed 
in the anterior end. Furthermore, RNAi of the Smed-
βcatenin-1 gene, which codes for β-catenin, resulted 
in posterior head regeneration3. It appears that the 
canonical pathway determines posterior tail formation. 
The role of the noncanonical pathways in regeneration 
is not thoroughly studied2. The noncanonical 
calcium pathway regulates intracellular calcium ion 
concentrations. It couples Dsh with a G-protein to 
stimulate production of either PLC or PDE, whose 
actions ultimately increase intracellular calcium ion 
levels2. In the noncanonical PCP pathway, Rac1, a 
GTPase, is activated. Studies have shown that Rac1 is 
involved in actin polymerization, and may play a role in 
cell structure and early embryogenesis2.
Our experiment involved four drugs: Imatinib, PZQ, 
EHT 1864, and U0126. Imatinib, a common anticancer 
drug, has been found recently to inhibit RTKs. RTKs 
phosphorylate the tyrosine components of β-catenin, 
which in turn stabilizes it, promotes its accumulation and 
binding to TCF and consequent gene transcription4. We 
hypothesized that the downregulation of the canonical 
pathway due to Imatinib would cause RTK inhibition, 
and consequently, posterior head formation during 
regeneration.  
The anthelmintic drug PZQ promotes the release of 
intracellular calcium ions5. Current theory suggests that 
PZQ targets membrane calcium channels, and through 
some unknown mechanism, causes an influx of calcium 
ions into the cell9. PZQ affects the Wnt noncanonical 
calcium pathway; its actions lead to an increased 
inhibition of gene transcription downstream of the 
pathway9. Previous experiments have shown that PZQ 
treatment caused planarian posterior head formation5. 
Therefore, we hypothesized that PZQ would cause 
posterior head growth. 
EHT 1864 inhibits the GTPase Rac1 by inhibiting its 
guanine nucleotide association6. This affects various 
components downstream and causes a number of 
unknown events. We hypothesized that the inhibition 
of the Rac1 by EHT 1864 would disrupt the normal 
functioning of planarian stem cells. 
U0126 inhibits MEK1. MEK1 protein functions in 
the MAPK pathway to activate ERK, which induces 
blastema cell (planarian stem cell) differentiation. Thus, 
MEK1 is essential for planarian development. The 
inhibition of MEK1 by U0126 limits ERK activity and 
thus limits blastema cell differentiation7. Since ERK is 
primarily involved with blastema cells on the anterior 
end7, we expected abnormal head formation on the 
planarians treated with U0126. 
A diverse set of pathways is involved in planarian A/P 
polarity formation. The canonical pathway is mainly 
involved in posterior regulation. Its activation in the 
posterior end of the planarian promotes transcription of 
certain genes that facilitate the posterior end to develop 
into a tail. The noncanonical pathways’ functions are 
unclear for the most part, but nonetheless they seem 
to complement A/P polarity formation due to their 
simultaneous activation with the canonical pathway. 
Finally, the MAPK pathway has the important role of 
regulating anterior regeneration. The main objective of 
the study, as presented previously, is to disrupt these 
pathways using drugs and to study whether A/P polarity 
formation is affected. 
MATERIALS AND METHOD
Drug Concentrations: 
For the drugs PZQ, EHT 1864, and Imatinib, we 
prepared five concentrations for each drug: 100 µM, 
50 µM, 25 µM, 12.5 µM, and 6.25 µM in spring water 
supplied by Carolina®. These dilution concentrations 
were estimations based off of research papers on these 
drugs and the IC50 of the drugs on non-planarian cells4,5. 
For U0126, the five dilution concentrations were 10 µM, 
5 µM, 2.5 µM, 1.25 µM, and 0.625 µM. U0126 dilutions 
are 10 times more diluted than the other three drugs 
because its IC50 is very low compared to the rest7. 
Each drug was given one 6-well plate to house the five 
dilutions. A control well with only spring water was set up 
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within the Imatinib plate. We had an inadequate supply 
of brown planarians after we had finished transferring 
the planarians, so we instead decided to use black 
planarians for the U0126 dilutions.
Planarian Drug Treatment: 
The planarians used were the brown and black planarians 
of the species Dugesia tigrina, from Carolina® that had 
been starved for 24 hours. The planarians were cut 
on iced plates by removing their heads approximately 
half way between the anterior end and the anterior end 
of the pharynx, and their tails at half way between the 
posterior end and the posterior end of the pharynx. The 
remaining fragments were washed in spring water and 
two trunk fragments were pipetted into each well. 
The worms were observed and photographed every 
24 hours for 8 days using an optical microscope with 
a camera attached and connected to a computer with 
appropriate software for image acquisition.
After 48 hours of drug treatment, the worms on each 
plate were transferred into a new plate with wells 
containing spring water only. 
RESULTS
EHT 1864 disintegrated planarians under high 
concentration and stunted planarian regeneration
EHT 1864 was fatal to the planarians at concentrations 
of 50µM and 100µM. After 18 hours of EHT 1864 
treatment at 50 and 100 µM concentrations, the 
planarians disintegrated (Figure 1A), leaving behind 
body remnants (For this reason, we did not plate these 
planarian in the spring water after the 48 hours). In the 
EHT 25 µM, the worms never fully regenerated (Figure 
1B) even after eight days, and seemed to be unable to 
move. Both worms in the plate squirmed and twitched 
in place, and failed to respond when prodded with 
forceps. One of the worms developed a growth on the 
back after 3 days (Figure 1C); the growth was round 
and raised on the back. In addition to the growth, the 
worm seemed to have trouble moving and flipping back 
over. By the next day, however, the growth disappeared 
and in its place was a small white dot. There was also 
a bit of mucus on the end of the worm (Figure 1D). 
The worms in the 12.5µM well (Figure 1E) exhibited a 
greater degree of regeneration, with visible eyespots. 
However, the regeneration appeared to be incomplete 
when compared to the control (Figure 1F), with the tail 
regeneration stunted and the anterior head still in the 
process of regeneration. In the 6.25µM, we found one 
worm (Figure 1G) that had fully regenerated within a 
day of being cut. 
Imatinib produced no abnormal changes
All of the worms in all wells of the Imatinib plate 
exhibited normal anterior and posterior regeneration. 
After 72 hours, eyespots were visible in all planarians 
in the Imatinib plate except for those in the 100 µM well 
(Figure 2A). After 96 hours (4 days), eyespots were 
clearly visible on the planarians in all wells including the 
100 µM (Figure 2B). By the end of the experiment, after 
192 hours (8 days), it was clear that both the head and 
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Figure 1 EHT 1864 Treated Planarians A. EHT 1864 50µM. 
The worm has fully disintegrated and no longer shows the 
same body outline of typical planarians. Scale bar indicates 
2.5mm. B. EHT 1864 25µM, 8 days. The worms have 
shown little signs of regenerations, and are unable to move 
out of place. Scale bar indicates 2.5mm.  C. EHT 1864 
25µM, 3 days.  The worm has a strange growth on the back 
of its body, and is having trouble twisting over. Scale bar 
indicates 2.5mm.  D. EHT 1864 25µM, 4 Days. The growth 
is no longer present. Instead, the worm exhibits a white 
spot (indicated by arrow), and has some mucus coming 
off of the worm. (Not Shown) Scale bar indicates 1 mm. E. 
EHT 1864 12.5µM, 5 days.  The worms have shown signs 
of eye development (blue arrow), but have not developed 
a fully formed head or tail.  F. Control worm, 5 days.  Near 
complete regeneration of head and tail. Pronounced head 
shape has developed. Scale bar indicates 1 mm. G. EHT 
1864 6.25µM, 1 day. Fully regenerated worm after just one 
day. Complete with head and tail development. (Tail not 
shown) Scale bar indicates 1 mm.
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tail of all Imatinib treated planarians had regenerated 
(Figure 2C, 2D). There were no abnormal tail growth or 
abnormal regeneration seen in the planarians. 
PZQ produced no abnormal changes 
PZQ treated planarians showed normal anterior and 
posterior regeneration. After 96 hours (4 days), all 
planarians in all PZQ wells except those in the 100 
µM well formed visible eyes on the anterior blastema, 
indicating head regeneration (Figure 3A). After 120 
hours (5 days), the planarians in the 100 µM well formed 
visible eyes. After 192 hours (8 days), all planarians 
exhibited normal head and tail growth (Figure 3B, 3C, 
3D). 
U0126 produced abnormal eye and head regeneration 
in planarians 
In the 10µM and 5µM concentrations, we noticed 
abnormal eye growth on the worms. After 72 hours, we 
Figure 2 Imatinib Treated Planarians A. Imatinib 50µM, 3 days. The planarians 
show clear eye development three days after being exposed to the drug (eyes 
indicated by arrows). The development of the eyes coincided with the development 
of the eyes within the control plate, indicating that Imatinib does not inhibit the 
regeneration and development of the head at concentrations as high as 50µM. 
Scale indicates 0.75 mm. B. Imatinib 100µM 4 days. Even at the highest 
concentration, the planarian is showing signs of eye development indicating minimal 
effect of the drug on regeneration. Scale indicates 0.75 mm. C. Imatinib 100 µM, 
head, 8 days. Scale indicates 0.75 mm. D. Imatinib 100µM, tail, 8 days. After 8 days, 
the planarian has a fully regenerated head and tail, showing that the worm is able to 
fully regenerate with no consequence after being exposed to the Imatinib. Scale 
indicates 0.75 mm. 
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indicating that Imatinib does not inhibit the regeneration 
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50µM. Scale indicates 0.75 mm. B. Imatinib 100µM 4 days. 
Even at the highest concentration, the planarian is showing 
signs of eye development indicating minimal effect of the 
drug on regeneration. Scale indicates 0.75 mm. C. Imatinib 
100 µM, head, 8 days. Scale indicates 0.75 mm. D. Imatinib 
100µM, tail, 8 days. After 8 days, the planarian has a fully 
regenerated head and tail, showing that the worm is able to 
fully regenerate with no consequence after being exposed 
to the Imatinib. Scale indicates 0.75 mm.
Figure  P=4 Treated Planarians A. 3=4 50µM Day 4. Clear development of eyes 
on the anterior, indicating that there was minimal impact of the drug on regeneration. 
Development of eyes was consistent with the timeframe of the control worms. B, C, D. 
Development of the head and tails after 8 days in 3=4 .5µM.  B is the head, C is the 
tail, and D is the entire body. There are no observable defects or abnormalities. Scale 
indicates 1.5 mm for all except D. 2n D, Scale indicates 3 mm. 
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i ure 3 PZQ Treated Planarians A. PZQ 50µM Day 4. 
Clear development of eyes on the anterior, indicating that 
th re was minim l impact of the drug on regeneration. 
Development of eyes was consistent with the timeframe 
of the control worms. B, C, D. Development of the head 
and tails after 8 days in PZQ 6.25µM.  B is the head, C is 
the tail, and D is the entire body. There are no observable 
defects or abnormalities. Scale indicates 1.5 mm for all 
except D. On D, Scale indicates 3 mm.
Figure  82 Treated Planarians A. 801 5µM 3 days. The worm had developed 
an eye, but did not show a sign of a second eye (a condition Nnown as cyclopia). B. 
801 10µM 4 days. The worm had developed the same cyclopia condition as the 
5µM concentrations. C. The worms have expanded eyes, but still seem to be part of a 
single eye, fused together. D. 801 10 µM  days. A planarian had an inconspicuous 
eye on the left, the other overly large. Scales all indicate 1mm. 
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Fi re 4 U0126 Treated Planarians A. U0126 5µM 3 days. 
The worm had developed an eye, but did not show a sign 
of a seco d eye (a condition know  as cyclopia). B. U0126 
10µM 4 days. The worm had developed the same cyclopia 
condition as the 5µM concentrations. C. The worms have 
expanded eyes, but still seem to be part of a single eye, 
fused together. D. U0126 10 µM 6 days. A planarian had 
an inconspicuous eye on the left, the other overly large. 
Scales all indicate 1mm.
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noticed that a planarian in 5 µM well had only one eye 
on its anterior blastema (Figure 4A). The next day, at 96 
hours, we noticed only one visible eye forming on the 
planarian in the 10 µM (Figure 4B). As for the planarians 
in the 5 µM well, we observed that the previously 
identified single eyes became larger and wider, almost 
slit-like (Figure 4C). At 120 hours (5 days), the single 
eyed planarians in 10 µM and 5 µM were still spotted 
with no signs of a second visible. At 144 hours (6 days), 
however, we observed a very faint and inconspicuous 
second eye on all worms in the 10µM and 5µM worms 
(Figure 4D). It appeared that in the 10 µM well, the two 
planarians had eyes of different sizes, one of which 
has a significantly larger eye on the left, the other a 
significantly larger eye on the right; in the 5 µM well, the 
two planarians had eyes of roughly equal size, but are 
joined together so they appeared to be only one single 
eye slit. All the planarians in the other concentrations 
(2.5 µM, 1.25 µM, 0.625 µM) exhibited normal eye 
development and regeneration. Normal eyes in those 
low concentration wells were visible starting after 72 
hours. 
DISCUSSION 
EHT 1864 disintegrated the planarians at concentrations 
of 100 µM and 50 µM, consistent with the idea that the 
high concentrations inhibited much of the Rac1 within 
the planarians, thus disrupted actin polymerization and 
cytoskeletal integrity (also a possible explanation of the 
growth observed). The planarians in the 25µM well also 
exhibited stunted regeneration and movement. This 
may be due to EHT 1864 binding to Rac1 outside of the 
Wnt pathway as well. Rac1 is a multipurpose protein 
responsible for cell growth and motility within the body 
in humans8. Planarian Rac1 may have similar roles. 
This would explain the planarians’ failure to regenerate, 
because the stem cells within the planarians would be 
unable to move towards the wound and proliferate.
Imatinib did not cause abnormal regeneration. Since it 
inhibits RTKs, and there are no changes in regeneration, 
we suggest that RTKs play a non-essential role in the 
Wnt pathway and the other pathways associated with 
regeneration. The downregulation of the canonical 
pathway due to Imatinib inhibition of RTKs would cause 
posterior head growth, if the RTKs were integral to the 
pathway. However, the possibility remains that the drug 
concentrations were not sufficient to cause inhibition, or 
the treatment time was not sufficient. 
Carefully following the procedures of Chan and 
Marchant’s (2011) study5 on PZQ’s effects on planarians, 
we expected both anterior and posterior head formation 
during regeneration, which did not occur. The previous 
study used D. japonica as their test subjects, whereas 
we used D. tigrina. The paper mentioned that PZQ has 
different levels of penetrance on different species of 
planarians. Thus, the lack of posterior head formation 
might be due to the low level of PZQ penetrance on 
D. tigrina, or that the D. tigrina noncanonical calcium 
pathway does not play as large a role as that of D. 
japonica. We propose that the two species may have 
different noncanonical calcium pathways, for the same 
drug yielded different results. 
U0126 treatment effected unusual eye formation. At 
10µM and 5µM, a cyclops condition was first observed, 
and then an abnormally large eye next to a minuscule 
eye. In contrast, the eyes of planarians in the control 
group developed at the same rate and have roughly 
the same size each time they were photographed 
(representative of the normal mode of planarian 
eye development). U0126’s inhibition of the MEK1 
at high concentrations resulted in low ERK levels, 
downregulation of the MAPK pathway, and abnormal 
cell differentiation into eye cells. This is supported by the 
observation that at concentrations of 0.625, 1.25, and 
2.5 μM, the planarians regenerated normal eyes earlier 
than those in 5 and 10 μM. The general trend is that the 
higher the U0126 concentration, the more abnormal the 
eye development. Since the MAPK pathway seems to 
be directly involved in eye development, we speculate 
that it may regulate a gene that participates in eye 
development. 
Though the experiment was successful, we did make 
some errors. For instance, in the 6.25µM EHT 1864 
plate, we found a worm (Figure 5G) that had fully 
regenerated within a day. We decided to replate a new 
6.25µM EHT 1864 well the next day. The other worms 
in the original 6.25µM and the new 6.25µM wells did 
not show complete regeneration, confirming that there 
was a human error in worm cutting. Furthermore, our 
experimental procedure had some limitations, primarily 
because we had to cut the planarians under microscopes 
and approximate the cutting locations; different cutting 
locations might result in different rates of regeneration. 
FUTURE DIRECTIONS
Due to time constraints, we were unable to repeat our 
drug assays. To further confirm the validity of our results, 
more tests need to be conducted. 
Furthermore, more research need to be conducted on the 
drugs. The major limitation of the research is that it relies 
heavily on pure observational analysis and is lacking in 
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quantitative measurements. Future experiments can 
complement observations with procedures such as 
protein expression staining to quantify the extent of 
protein expression during development. In addition, in 
order to determine whether the disruption of the Wnt 
pathway is solely responsible for the results from EHT 
1864, a second experiment using a drug, or RNAi, 
that is specific for the noncanonical PCP pathway 
needs to be performed. More research is needed to 
determine the cause behind the different responses 
of D. tigrina and D. japonica to PZQ. Furthermore, 
the concentration of Imatinib should be increased 
to clarify whether RTKs serve an important role in 
planarian regeneration, to eliminate the possibility of 
having inadequate concentration. Finally, in order to 
elucidate the functions of the MAPK pathway in regards 
to eye development, RNAi should be used on further 
downstream components. 
ABBREVIATIONS
Abbreviation Full Form
A/P Anterior/Posterior
MAPK  Mitogen-activated protein  
 kinases
RTK Receptor Tyrosine Kinase
PZQ Praziquantel
Dsh Dishevelled
TCF Transcription Factor
sFRP Secreted Frizzle Related  
 Protein
PCP Planar cell polarity
RNAi RNA interference
ERK (a.k.a. MAPK)  Extracellular-signal-regulated 
 kinases
MEK1 (a.k.a MAP2K1) Dual specificity  
 mitogen-activated protein  
 kinase kinase 1
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